UNSPSC 51384208: Loxoprofen sodium

This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H17O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NDC2M7399S, chemically known as benzeneacetic acid, alpha-methyl-4-((2-oxocyclopentyl)methyl)-, sodium salt, dihydrate but more generally known as loxoprofen sodium, which bears US NIH Compound Identifier 157322. European Medicines Agency schedules Loxoprofen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02978MIG.

Most nations, for tariff and trade purposes, schedule loxoprofen sodium under HS 29183000 and SITC 51395. As of Q4 2014, LOXOPROFEN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCC(CC1)CC2CCCC2=O)C(=O)[O-].[NA+].

UNSPSC 51384208 Loxoprofen sodium is a Commodity code that shows limited recent state and local procurement activity aligned with its nominal scope. The single identifiable opportunity in the recent record—Seminole County, Florida's IFB 60459723LAS—does not involve loxoprofen sodium procurement at all; instead, the county solicited naloxone and drug deactivation systems for community health support. State and local governments use Commodity codes in this pharmaceutical range to acquire specific active pharmaceutical ingredients and finished medicinal products for public health, emergency response, and clinical programs, but current activity under this code does not reflect that pattern.

Seminole County issued the naloxone and drug deactivation systems IFB on June 30, 2026, with a response deadline of July 26, 2023, calling for 1,900 units of naloxone and 800 safe drug deactivation systems annually on a quarterly-delivery schedule to the Seminole County Community Health Building in Sanford. The county required E-Verify compliance, drug-free workplace certification, workers' compensation and liability insurance, and included a three-month probationary termination clause. The contract term ran two years with a one-year renewal option and was potentially funded through FEMA. No recent comparable loxoprofen sodium opportunities appear in the record, making current market activity under this specific code unclear.